Table 2.

Univariate and multivariate analyses of prognostic variables for overall survival in whole AML patients

Variables	Overall Survival
	Univariate Analysis		Multivariate Analysis
	HR (95% CI)	P value	HR (95% CI)	P value
Age	2.532 (1.534–4.179)	<0.001	1.310 (0.731–2.346)	0.364
WBC	3.021 (1.829–4.990)	<0.001	2.277 (1.302–3.981)	0.004*
Cytogenetic abnormalities’ classifications	2.076 (1.503–2.867)	<0.001	1.962 (1.306–2.948)	0.001*
Circ_0002232 expression	1.817 (1.024–3.223)	0.041	0.874 (0.409–1.866)	0.727
FLT3-ITD mutation	0.881 (0.397–1.954)	0.755	–	–
NPM1 mutation	1.697 (0.672–4.287)	0.263	–	–
CEBPA mutation	0.891 (0.380–2.093)	0.791	–	–
c-KIT mutation	0.586 (0.142–2.416)	0.460	–	–
N/K-RAS mutation	2.753 (1.071–7.081)	0.036	3.000 (1.155–7.795)	0.024*
IDH1/2 mutation	5.328 (0.697–40.737)	0.107	–	–
DNMT3A mutation	1.644 (0.652–4.147)	0.292	–	–
U2AF1 mutation	4.609 (1.073–19.801)	0.040	1.593 (0.202–12.584)	0.659
SRSF-2 mutation	2.610 (0.353–19.303)	0.347	–	–

Notes: Prognostic variables included WBC (≥30×10⁹ vs <30×10⁹/L), patients’ age (≤60 vs >60 years), cytogenetic abnormalities’ classifications (favorable vs intermediate vs poor), circ_0002232 expression level (Low vs High), and gene mutations (mutant vs wild-type). Variables with P<0.05 in univariate analysis were included into multivariate analysis. *Indicated statistical significance (P<0.05).

Abbreviations: HR, hazard ratio; CI, confidence interval; WBC, white blood cell.